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Abstract
Objectives Cervical cancer is the most common malig-
nancy among Nepalese women. Rational prevention mea-
sures are informed by epidemiological data on human
papillomavirus (HPV) prevalence.
Methods Cervical specimens were obtained from 932
married women aged 15–59 years from the general popu-
lation of Bharatpur, Nepal, as well as from 61 locally
diagnosed invasive cervical cancers (ICC). HPV was
detected using a GP5?/6? PCR-based assay.
Results Among the general population, the overall prev-
alence of HPV was 8.6% (6.1% for high-risk types).
Prevalence of abnormal Pap smears was 3.6%, including
five high-grade squamous intraepithelial lesions. Residence
in slum housing, lower education level, C3 sexual partners
in a woman’s lifetime, and husband’s extramarital affairs
were significantly associated with HPV positivity. HPV
prevalence was relatively constant across all age groups.
HPV16 was the most common type, both among the gen-
eral population (1.9%) and among 54 women with HPV-
positive ICC (68.5%). HPV18 (22.2%) and 45 (5.6%) were
also common in ICC.
Conclusions Nepal has an intermediate burden of HPV
infection, lower than many areas in India and China.
Approximately 80% of cervical cancer in Nepal is theo-
retically preventable by HPV16/18 vaccines. In the
meantime, screen-and-treat approaches should be encour-
aged to overcome difficulties that were encountered to
recall women with screening-positive findings.
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Abbreviations
CI Confidence interval
HSIL High-grade squamous intraepithelial lesions
HPV Human papillomavirus
HPV16/18 HPV16 and/or 18
IARC International Agency for Research on Cancer
ICC Invasive cervical cancer
OR Odds ratio
Introduction
Nepal is a land-locked country between India and China.
Its 27 million inhabitants are divided approximately
equally between the mountain/hills and the low plains
bordering India. The adult literacy rate is estimated at 49%
[1], and 24% of the population lives below the poverty line
[2]. Life expectancy at birth is 61 years for men and
women alike [3].
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Cervical cancer is the most commonly reported malig-
nancy among women in Nepal [4], although no population-
based estimates of cervical cancer incidence exist. Neither
are there any data on the prevalence of high-risk human
papillomavirus (HPV) infection in Nepal, which, in the
absence of good-quality screening, is known to correlate
with cervical cancer incidence [5].
The establishment of the viral etiology of cervical cancer
has raised the hopes for primary and secondary prevention
through HPV vaccination [6] and HPV DNA test-based
screening [7, 8], respectively. The rationale and planning of
such measures greatly benefit from knowledge of overall,
age-, and type-specific HPV prevalence in women with and
without cancer. To this end, the International Agency for
Research on Cancer (IARC) has carried out surveys in
representative samples of women worldwide [9].
The purpose of the study was to assess the prevalence of
type-specific HPV infection in the general female popula-
tion and in invasive cervical cancer (ICC) in Nepal.
Materials and methods
HPV prevalence survey
Study methods were similar to those used for previous
IARC HPV prevalence surveys [9]. The study area inclu-
ded four semi-urban districts (Ganesthan, Muktinagar,
Naurange and Bhojad) of Bharatpur municipality, Chita-
wan Province, in the low plains of Nepal. The study pur-
pose was to enroll approximately 100 women from the
general population in each five-year age group between
15–19 and 54–59 years. All mentally and physically
competent women aged 15–59 years were eligible for the
study, regardless of their marital status. All women were
enumerated at their homes by local community workers
and invited to the study clinic, which was set up in the
community specifically for the present study between
October 2006 and March 2007.
Of the 1,606 invited women, 514 (32.0%) did not accept
the invitation, including 42 who had never been married.
Refusal rates were 47, 13, 10, and 49% among women aged
15–24, 25–34, 35–44, and 45–59 years, respectively. The
most common reasons for non-participation were lack of
perception of the need to undergo screening in the absence
of symptoms (n = 195) and lack of permission of husband
(n = 63). In addition, among the 1,092 women who
accepted the invitation to come to the study clinic, 113
eventually refused to undergo a pelvic examination,
(including 54 unmarried women who reported themselves
to be virgins and 18 pregnant women) and hence were
unable to provide a cervical cell specimen. In the end, no
unmarried woman provided a cervical cell specimen.
An interview was administered by one of two female
interviewers in the local dialect. The structured question-
naire included information on socio-demographic charac-
teristics, reproductive and menstrual factors, sexual habits
of women and their husbands, and lifetime use of contra-
ceptive methods.
A total of 979 women underwent a pelvic examination
by a midwife or female doctor. After the preparation of a
conventional Pap smear, a sample of exfoliated cervical
cells from the endocervix and ectocervix was collected
with a cervexbrush (Rovers Medical Devices B.V., Oss, the
Netherlands). After being inserted into the endocervical
canal and rotated gently 180, the brush containing cellular
material was placed in a vial containing PreservCyt media
(Hologic, Inc., Marlborough, MA, USA).
Pap smears were read by a pathologist (S.S.) at the B.P.
Koirala Memorial Cancer Hospital, Bharatpur, the national
referral centre for all cancer in Nepal.
Women with ICC
Tumor biopsies, formalin fixed and embedded in paraffin,
were retrieved for all women (n = 68) with histologically
confirmed ICC to B.P. Koirala Memorial Cancer Hospital
during 2006.
Ethical approval
All participants for the HPV prevalence survey signed
informed consent forms according to the recommendations
of the IARC and the B.P. Koirala Memorial Cancer Hos-
pital ethical review committees, both of which approved
the present study.
HPV detection
HPV testing was performed on exfoliated cervical cells and
ICC biopsies at the Department of Pathology at the Vrije
University Medical Center, Amsterdam, The Netherlands.
DNA was extracted from the PreservCyt sample using
magnetic beads (Macherey-Nagel, Du¨ren, Germany) on a
robotic system (Hamilton, Germany), according to the
manufacturer’s instructions. ICC biopsies were sectioned
using a ‘sandwich’ approach, whereby inner tumor sections
were destined for HPV testing and outer sections for his-
tological confirmation of tumor tissue. One or more five-lM
sections representing approximately 1 cm2 of tissue were
predigested with proteinase K after which DNA was
extracted using magnetic beads (Macherey-Nagel).
Beta-globin PCR analysis was performed firstly to
confirm the presence of human DNA in all specimens [10].
The overall presence of HPV DNA was determined by
performing a general primer GP5?/6? -mediated PCR,
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which permits the detection of a broad spectrum of genital
HPV types at the subpicogram level [11]. HPV positivity
was assessed by hybridization of PCR products in an
enzyme immunoassay using two HPV oligoprobe cocktails
which, together, detect the following 44 HPV types: HPV6,
11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45,
51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 66, 67, 68, 69, 70,
71 (equivalent to CP8061), 72, 73, 81 (equivalent to
CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to
MM7), 84 (equivalent to MM8), cand85, 86, cand89
(equivalent to CP6108), and JC9710. Subsequent HPV
typing was performed by reverse-line blot hybridization of
PCR products, as described previously [12]. HPV types
considered high-risk for this analysis included HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 [13].
All other HPV types were considered low-risk.
Statistical analysis
Crude, age-stratified, and age-standardized (world standard
population [14]) HPV prevalence with 95% confidence
intervals (CIs) was estimated.
Odds ratios (ORs) for HPV positivity and corresponding
95% CIs were calculated by means of unconditional
logistic regression equations adjusted for age (\25, 25–34,
35–44, and 45–59 years). Adjustment for additional vari-
ables was also performed, but not shown. The statistical
significance of trends for ORs was assessed by considering
the categorical variables as a continuous variable in the
logistic model.
Prevalence ratios and corresponding 95% CIs were used
to compare the relative frequency of the most common
HPV types in HPV-positive ICC with that among cyto-
logically normal HPV-positive women from the HPV
prevalence survey.
Results
HPV prevalence survey
Of 979 married women who provided cervical cell sam-
ples, 36 had inadequate HPV DNA results (i.e., beta-globin
PCR negative), and an additional 11 had inadequate
cytology, leaving 932 women with valid results for both
HPV and cytology. Among them, 34 (3.6%) had abnormal
cytological findings, including 29 (3.1%) atypical squa-
mous cells of undetermined significance/low-grade squa-
mous intraepithelial lesions, and five (0.5%) high-grade
squamous intraepithelial lesions (HSIL).
Overall HPV prevalence was 8.6%, being 20.6 and 8.1%
among women with and without cervical abnormalities,
respectively (Table 1). The corresponding prevalence age-
standardized to the world population was also 8.6%. In
total, 64 (6.9%) women had single-type infections, and 16
(1.7%) had multiple-type infections. Prevalence of high-
risk types was 6.1%, compared to 3.8% for low-risk types.
The most common high-risk types among women with
normal cytology were HPV16 (1.5%), 58 (0.9%), 56
(0.7%), 18 (0.6%), and 52 (0.5%). HPV42 (0.8%) was the
most commonly detected low-risk type. HPV16 also pre-
dominated among women with cervical abnormalities,
including four out of five HSIL.
Figure 1 shows the age-specific prevalence of HPV,
classified hierarchically into 1) HPV16 and/or 18 (HPV16/
18), 2) other high-risk types and [3] low-risk types only.
Overall, HPV prevalence was not significantly different by
age group. However, the prevalence of HPV16/18
increased from 1.1% among women aged 15–24 years to
5.2% among women aged 45–59 years (p for trend by age
group = 0.02). Finer stratification of women aged less than
25 years revealed overall HPV prevalences of 8.9, 6.9,
and 7.2% among women aged less than 20, 20–22, and
23–24 years, respectively.
Table 2 shows the relationship between HPV positivity
and various characteristics of study participants, adjusted
for age. Significant differences in HPV positivity were
observed for residence in slum housing (OR = 2.96; 95%
CI: 1.76–4.98), education level (OR for none versus
higher = 2.41; 95% CI: 1.04–5.56), lifetime number of
sexual partners (OR for C3 vs. 1 partner = 4.09; 95% CI:
1.52–11.01), reporting of husband’s extramarital sexual
relationships (OR = 1.71; 95% CI: 1.04–2.80), and lack of
history of cervical cancer screening (OR = 1.88; 95% CI:
1.01–3.51). These associations remained materially
unchanged when additionally adjusted for residence in
slum housing, education level, and/or lifetime number of
sexual partners, as appropriate (data not shown).
Religion, occupation, age at first marriage, age at first
sexual intercourse, and number of births were not signifi-
cantly related to HPV positivity in either adjustment model
(Table 2) and neither were smoking or chewing tobacco
habits (reported by 18.6 and 6.2% of women, respectively),
hormonal contraceptive use (reported by 43.4% of women),
condom use (18.3%), intrauterine device use (5.1%), or a
history of spontaneous (26.5%) or induced abortions
(26.0%) (data not shown).
Women with ICC
Biopsies that were beta-globin PCR negative (n = 5) or
without histological evidence of tumor (n = 2) were
excluded. Among the remaining 61 ICC biopsies, six were
adenocarcinoma, and the rest were squamous-cell carci-
noma. The median age of women with ICC was 50 years
(range: 29–60 years). Seven squamous-cell carcinoma
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Table 1 Prevalence of human papillomavirus (HPV) types by cytological findings and overall among 932 married women. Bharatpur, Nepal,
2006–2007
HPV type Normal cytology (n = 898) Abnormal cytology (n = 34) Total (n = 932)
Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
HPV- – – 825 (91.9) – – 27 (79.4)a – – 852 (91.4)
HPV? 59 14 73 (8.1) 5 2 7 (20.6) 64 16 80 (8.6)
HR HPV? 37 13 50 (5.6) 5 2 7 (20.6) 42 15 57 (6.1)
LR HPV? 22 11 33 (3.7) 0 2 2 (5.9) 22 13 35 (3.8)
High-risk infections
16 10 3 13 (1.5) 3b 2b 5 (14.7) 13 5 18 (1.9)
18 4 1 5 (0.6) 0 0 0 4 1 5 (0.5)
31 1 0 1 (0.1) 1 0 1 (2.9) 2 0 2 (0.2)
33 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
35 2 1 3 (0.3) 0 0 0 2 1 3 (0.3)
39 4 0 4 (0.5) 0 0 0 4 0 4 (0.4)
45 0 2 2 (0.2) 0 0 0 0 2 2 (0.2)
51 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
52 2 2 4 (0.5) 1 0 1 (2.9) 3 2 5 (0.5)
56 2 4 6 (0.7) 0 0 0 2 4 6 (0.6)
58 6 2 8 (0.9) 0 0 0 6 2 8 (0.9)
59 0 0 0 0 0 0 0 0 0
68 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
73 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
82 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
Subtotal 37 17 54 - 5 2 7 - 42 19 61 -
Low-risk infections
6 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
11 0 0 0 0 0 0 0 0 0
26 0 0 0 0 0 0 0 0 0
30 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
34 0 0 0 0 0 0 0 0 0
40 0 0 0 0 0 0 0 0 0
42 2 5 7 (0.8) 0 1a 1 (2.9) 2 6 8 (0.9)
43 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
44 0 0 0 0 0 0 0 0 0
53 0 0 0 0 0 0 0 0 0
54 0 0 0 0 0 0 0 0 0
55 1 0 1 (0.1) 0 0 0 1 0 1 (0.1)
61 0 0 0 0 0 0 0 0 0
64 0 0 0 0 0 0 0 0 0
66 0 0 0 0 0 0 0 0 0
67 1 3 4 (0.5) 0 0 0 1 3 4 (0.4)
69 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
70 4 0 4 (0.5) 0 0 0 4 0 4 (0.4)
72 0 0 0 0 0 0 0 0 0
81 1 0 1 (0.1) 0 0 0 1 0 1 (0.1)
86 3 0 3 (0.3) 0 0 0 3 0 3 (0.3)
CP6108 1 0 1 (0.1) 0 0 0 1 0 1 (0.1)
JC9710 2 4 6 (0.7) 0 1a 1 (2.9) 2 5 7 (0.8)
Subtotal 21 13 34 - 0 2 2 - 21 15 36 -
X 1 0 1 (0.1) 0 0 0 1 0 1 (0.1)
Total infections 59 30 89 - 5 4 9 - 64 34 98 -
X uncharacterized type
a One high-grade squamous intraepithelial lesion (HSIL)
b Two HSIL
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biopsies were HPV negative. The comparison of type-
specific HPV prevalence in the 54 women with HPV-
positive ICC and the 73 HPV-positive women with normal
cytology from the HPV prevalence survey is shown in
Table 3. HPV16 was found in 37 (68.5%) HPV-positive
ICC biopsies. The next most common types were HPV18
(22.2%) and 45 (5.6%). Prevalence ratios in women with
ICC versus those with normal cytology were 3.85 (95% CI:
2.79–5.32) for HPV16; 3.24 (95% CI: 1.84–5.71) for
HPV18; 2.03 (95% CI: 0.65–6.20) for HPV45; and 0.13
(95% CI: 0.04–0.39) for the combination of other high-risk
types. Multiple-type infections were much less common in
HPV-positive women with ICC than in HPV-positive
women with normal cytology (Table 3).
Discussion
The major finding of this present study, the first undertaken
in Nepal, is that the burden of HPV infection in the general
population (8.6%) is somewhat lower than that observed in
previous studies performed using the same HPV testing
protocol in neighboring countries (e.g., 17% in Tamil
Nadu, India, [15] and 15–18% range in three provinces in
China [16–18]), and much less than in the high-risk areas in
Asia and Africa (e.g., 35% in Mongolia [19] and 51% in
Guinea [20]). Nevertheless, HPV prevalence remained
greater than that in other areas in Asia (e.g., 2% in Hanoi,
Vietnam [21], 4% in Songkla, Thailand [22]), and in Eur-
ope [23].
One of the other main aims of the IARC HPV preva-
lence surveys is to describe the variations of age- and type-
specific HPV prevalence by geographical region. The age-
specific curve of HPV prevalence in Nepal resembled the
flat age curves reported previously in some low-resource
countries in Asia and Africa [15–18, 24], albeit at a lower
level of HPV prevalence. It clearly differed, on the other
hand, from the steep decrease in HPV prevalence seen by
age in high- and medium-resource countries in Europe, the
Americas, and Asia [23, 25].
As in previous IARC HPV prevalence surveys in Asia
[15–18], the gynecological exam was acceptable only to
married women, so, the HPV prevalence estimate repre-
sents that in married women only. Nevertheless, age at first
marriage (median = 17 years, intraquartile range 15–19)
was relatively early, and 91% of participants reported an
age at first sexual intercourse that was the same as, or
greater than, age at first marriage, suggesting that marriage
is a good proxy for sexual activity in this population.
HPV16/18 prevalence, however, was highest among older
women. HPV16/18 infections in older women are more
likely to represent persistent infections [26] and are more
likely to progress to cancer than other high-risk types [27].
As expected, the strongest risk factors for HPV posi-
tivity were confirmed, as elsewhere [28], to be the sexual
behavior of women and their husbands. Nevertheless, both
the percentage of women who reported two sexual partners
or more in their lifetime (9.9%) and the prevalence of
husband’s extramarital sexual relationships (32.1%) were
relatively low compared to similar surveys in other geo-
graphical areas (ranges: 6–64 and 12–100%, respectively)
[16–19, 28, 29]. A fourfold elevated risk of HPV positivity
was, however, detected among the 2.6% of women who
reported three sexual partners or more in their lifetime,
which included at least four known commercial sex
workers.
Residence in slum housing, low education level, and
absence of previous cervical cancer screening were also
associated with HPV positivity in this population, even
after adjustment for sexual behavior, suggesting some
association between lower socio-economic status and HPV
prevalence in Nepal. Of note, the relationship between
education level and HPV prevalence in previous IARC
surveys in Asia included inverse [25] and direct associa-
tions [21, 22] as well as no relationship [16].
A pilot project of screening by visual inspection of
5,000 women was undertaken at the B.P. Koirala Memorial
Cancer Hospital between 2003 and 2005. Therefore, the
reported percentage of previous cervical cancer screening
in our present study (24.6%) is expected to be much higher
than the national average, and to largely reflect a history of
visual inspection.
As in most previous similar studies, HPV16 was con-
firmed to be the most common type in the whole range of
women considered, i.e., 1.5, 14.7, and 68.5%, respectively,
in cytologically normal and abnormal women and in
women with HPV-positive ICC [9, 30]. HPV52 and 58,
however, were not as predominant as in similar surveys in
China [16–18]. We also confirmed that the type distribution
Fig. 1 Age-specific prevalence of human papillomavirus (HPV)
DNA by HPV type(s) among 932 married women. Bharatpur, Nepal,
2006–2007
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Table 2 Odds ratios (ORs) for
human papillomavirus (HPV)
positivity and corresponding
95% confidence intervals (CIs)
according to selected
characteristics among 932
married women. Bharatpur,
Nepal, 2006–2007
a Some figures do not add up to
the total because of few missing
b Adjusted for age
Characteristicsa N women HPV-positive ORb 95% CI
n (%)
Age (years)
\25 186 14 (7.5) 1 –
25–34 298 22 (7.4) 0.98 (0.49–1.97)
35–44 274 28 (10.2) 1,40 (0.72–2.73)
45–59 174 16 (9.2) 1.24 (0.59–2.63)
v2 1 for trend 0.98 p = 0.321
Religion
Hindu 789 63 (8.0) 1 –
Buddhist 117 15 (12.8) 1.69 (0.92–3.08)
Other 26 2 (7.7) 0.96 (0.22–4.15)
Occupation
Unemployed 744 67 (9.0) 1 –
Employed 188 13 (6.9) 0.74 (0.40–1.38)
Residence in slum housing
No 798 56 (7.0) 1
Yes 134 24 (17.9) 2.96 (1.76–4.98)
Education level
Higher than secondary 147 7 (4.8) 1 –
Primary/secondary 361 27 (7.5) 1.65 (0.70–3.90)
None 424 46 (10.9) 2.41 (1.04–5.56)
v2 1 for trend 5.24 p = 0.022
Age at 1st marriage
C19 280 19 (6.8) 1 –
16–18 352 33 (9.4) 1.44 (0.79–2.62)
B15 299 28 (9.4) 1.42 (0.76–2.66)
v2 1 for trend 1.09 p = 0.297
Age at 1st intercourse
C19 286 19 (6.6) 1 –
16–18 373 33 (8.9) 1.38 (0.76–2.50)
B15 269 28 (10.4) 1.67 (0.89–3.11)
v2 1 for trend 2.59 p = 0.108
Lifetime number of sexual partners
1 828 68 (8.2) 1 –
2 67 5 (7.5) 0.90 (0.35–2.32)
C 3 24 6 (25.0) 4.09 (1.52–11.01)
v2 1 for trend 4.56 p = 0.033
Husband’s extramarital sexual relationships
No 588 40 (6.8) 1 –
Yes 278 31 (11.2) 1.71 (1.04–2.80)
History of cervical cancer screening
Yes 229 13 (5.7) 1 –
No 703 67 (9.5) 1.88 (1.01–3.51)
Number of births
0 45 4 (8.9) 1.11 (0.37–3.29)
1–2 472 38 (8.1) 1 –
3–5 322 27 (8.4) 0.94 (0.54–1.65)
C6 92 11 (12.0) 1.39 (0.63–3.05)
v2 1 for trend 0.18 p = 0.674
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among the general population was not representative of
that in women with cervical cancer from the same region,
with the relative importance of HPV16/18 being much
greater in ICC, accounting for a total of 89% (95% CI: 77–
96%) of HPV-positive cases. If seven (probably falsely)
HPV-negative ICC were included in the denominator,
HPV16/18-related ICC would represent 79% (95% CI: 66–
88%) of cases. This is consistent with the findings of a
meta-analysis, which reported that the fraction of ICC
attributable to HPV16/18 may be higher in the Indian
subcontinent than in China and other parts of East Asia,
and similar to that in Europe and the United States [30].
Furthermore, although multiple infections were frequent in
the general population, 98.1% of HPV-positive ICC were
infected with a single HPV type, highlighting the selection
of one high-risk type in the course of malignant
transformation.
Major strengths of our present study include a large and
population-based sample, the use of a standardized and
well-validated HPV test allowing comparisons with similar
studies around the world [9] and the presence of a con-
current series of women with ICC drawn from the same
study area. An overall participation rate of 70% was also
relatively high compared to previous similar studies in
Asia. However, there was a differential participation rate
by age, being lower in the extreme age groups. Although
HPV infection is asymptomatic, it is possible that lack of
participation could have affected HPV prevalence esti-
mates. The comparisons relative to other worldwide
regions remain consistent, however, even when restricted
to women aged 25–44 years, for whom participation
approached 90% in Nepal.
No large-scale cytology-based screening programs have
been performed in Nepal. Therefore, problems of sensi-
tivity and specificity in Pap smear reading are likely to
have existed, as suggested by the low HPV prevalence
(20%) among women with cytological abnormalities.
Detection of high-risk HPV DNA in HSIL, however, was
consistent with findings from elsewhere.
Finally, despite the availability of a fund to cover all
diagnostic and treatment costs, and repeated insistence by
the study staff, the greatest disappointment of the study was
the refusal of the women with HSIL to be referred to
colposcopy for diagnostic follow-up. This refusal might
have been related to delays incurred by the political unrest
in Nepal in 2006–2007 and some rumors of bleeding and
pain from women who had undergone biopsy and/or
cryotherapy in previous pilot screening programs.
Although efforts to follow up screening-positive women
continue, our experience highlights once again [31] how
lack of familiarity with the usefulness of screening and the
treatable nature of cervical cancer can act as strong barriers
to the accomplishment of complete follow-up and treat-
ment of screening-detected cervical lesions.
In conclusion, the prevalence of HPV infection in the
general population would suggest that Nepal, where cancer
registration is not available, is a country with intermediate
cervical cancer risk. Screen-and-treat approaches should be
encouraged to overcome the difficulties encountered in the
recall of women [32, 33]. The care HPV test, for example,
appears particularly promising [7]. In respect to the
potential benefit of vaccination, approximately 80% of
cervical cancer in Nepal would be prevented by a vaccine
including HPV16/18.
Table 3 Prevalence of selected human papillomavirus (HPV) types in 54 women with HPV-positive invasive cervical carcinomas (ICC)a and 73
HPV-positive women with normal cytology. Bharatpur, Nepal, 2006–2007
HPV type ICC (n = 54) Normal cytology (n = 73) ICC:Normal cytology
Total (%) Total (%) Prevalence ratio (95%CI)
16 37 (68.5) 13 (17.8) 3.85 (2.79–5.32)
18 12 (22.2) 5 (6.8) 3.24 (1.84–5.71)
45 3 (5.6) 2 (2.7) 2.03 (0.65–6.20)
Other high-risk types 3b (5.6) 32 (43.8) 0.13 (0.04–0.39)
Any low-risk type 0 32 (43.8) 0 (0–0.17)d
X 0 1 (1.4) 0 (0–52.72)d
Multiple infections 1c (1.9) 14 (19.2) 0.10 (0.01–0.68)
X uncharacterized type
CI confidence interval
a Seven HPV-negative cancers are not included
b One HPV31, one HPV33, and one HPV56
c HPV16 ? 18
d Exact 95% CIs
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